Boceprevir and telaprevir interact with some drugs used for HIV treatment (and vice versa). Most drug-drug interaction studies have been conducted using healthy HCV- and HIV-negative volunteers. Based on results from these studies, pharmacologists and regulatory authorities in the U.S. and Europe have made recommendations about which drugs should not be used together.
Some infectious disease experts disagree with the recommendations about drug-drug interactions because they have found that in clinical trials with HIV-positive people who were taking ART and boceprevir or telaprevir, adequate antiviral responses against both HCV and HIV were seen.
There are several possible reasons why experiments with HIV-negative volunteers yielded one set of results and clinical trials with HIV-positive people a different set of results, as follows:
As with many studies of co-infection so far, the number of participants in these studies was too small to draw meaningful conclusions. Fortunately, this situation is being addressed by the U.S. AIDS Clinical Trials Group (ACTG) and in France by the ANRS. Both organizations are recruiting co-infected volunteers to further study the complex drug-drug interactions that can occur when drugs for HIV and HCV are taken by the same person.
Burger DM. Interactions between antiretrovirals and direct acting antivirals. In: Program and abstracts of the 8th International Workshop on HIV and Hepatitis Co-infection, 30 May - 1 June 2012, Madrid, Spain.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Expert: Long-Awaited CDC HIV Report on Conception Options for Serodiscordant Couples Is Disappointing and Confusing|
|This Week in HIV Research: Stable Housing Improves Viral Suppression and CD4 Counts|
|Fat Gains Continue and Lean Mass Falls in Group on Long-Term HIV Therapy|
|The Curious Case of M184V, Part 1|
|Inflammation in the Brain Continues Even With Undetectable Plasma Viral Load|
|This Week in HIV Research: Maintenance Therapy Regimen Containing Lamivudine May Be Viable Option|